[HTML][HTML] Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease
PURPOSE The risk of immune checkpoint inhibitor therapy–related GI adverse events in
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease
H Abu-Sbeih, DM Faleck… - Journal of …, 2020 - mdanderson.elsevierpure.com
PURPOSE The risk of immune checkpoint inhibitor therapy-related GI adverse events in
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease
H Abu-Sbeih, DM Faleck, B Ricciuti… - Journal of Clinical …, 2020 - kclpure.kcl.ac.uk
PURPOSE The risk of immune checkpoint inhibitor therapy-related GI adverse events in
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease
H Abu-Sbeih, DM Faleck, B Ricciuti… - JOURNAL OF …, 2020 - iris.uniupo.it
PURPOSE The risk of immune checkpoint inhibitor therapy-related GI adverse events in
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
H Abu-Sbeih, DM Faleck, B Ricciuti… - Journal of Clinical …, 2020 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> The risk of immune checkpoint
inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel …
inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel …
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
H Abu-Sbeih, DM Faleck, B Ricciuti… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The risk of immune checkpoint inhibitor therapy–related GI adverse events in
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
H Abu-Sbeih, DM Faleck, B Ricciuti… - Journal of clinical …, 2020 - pubmed.ncbi.nlm.nih.gov
Purpose The risk of immune checkpoint inhibitor therapy-related GI adverse events in
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease
H Abu-Sbeih, DM Faleck, B Ricciuti… - JOURNAL OF …, 2020 - cris.unibo.it
PURPOSE The risk of immune checkpoint inhibitor therapy-related GI adverse events in
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease
H Abu-Sbeih, DM Faleck, B Ricciuti… - Journal of Clinical …, 2020 - ohiostate.elsevierpure.com
PURPOSE The risk of immune checkpoint inhibitor therapy-related GI adverse events in
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease
H Abu-Sbeih, DM Faleck, B Ricciuti… - Journal of Clinical …, 2020 - research.uniupo.it
PURPOSE The risk of immune checkpoint inhibitor therapy-related GI adverse events in
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …